ArticleTherapeutic advances in musculoskeletal disease2012
Juvenile dermatomyositis: new insights and new treatment strategies.
Article in Therapeutic advances in musculoskeletal disease, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- New onset of dermatomyositis/polymyositis during anti-TNF-α therapies: a systematic literature review.TheScientificWorldJournal · 2014Pooled it
- The value of quantitative muscle ultrasound in monitoring muscle and fascia inflammatory activity in juvenile dermatomyositis patients.Quantitative imaging in medicine and surgery · 2024Article
- Serum IgG Profiling of Toddlers Reveals a Subgroup with Elevated Seropositive Antibodies to Viruses Correlating with Increased Vaccine and Autoantigen Responses.Journal of clinical immunology · 2021Article
- Mapping the current psychology provision for children and young people with juvenile dermatomyositis.Rheumatology advances in practice · 2021Article
- Why is a paediatric respiratory specialist integral to the paediatric rheumatology clinic?Breathe (Sheffield, England) · 2020Review
- Calcinosis Biomarkers in Adult and Juvenile Dermatomyositis.Autoimmunity reviews · 2020Review
- Abatacept in the Treatment of Juvenile Dermatomyositis-Associated Calcifications in a 16-Year-Old Girl.Case reports in rheumatology · 2020Article
- Being on the juvenile dermatomyositis rollercoaster: a qualitative study.Pediatric rheumatology online journal · 2019Article
- Medications received by patients with juvenile dermatomyositis.Seminars in arthritis and rheumatism · 2018Article
- Expression of the OAS Gene Family Is Highly Modulated in Subjects Affected by Juvenile Dermatomyositis, Resembling an Immune Response to a dsRNA Virus Infection.International journal of molecular sciences · 2018Article
- The Vasculopathy of Juvenile Dermatomyositis.Frontiers in pediatrics · 2018Review
- Treatment of Juvenile Dermatomyositis: An Update.Paediatric drugs · 2017Review
- Juvenile dermatomyositis: a tertiary center experience.Clinical rheumatology · 2017Article
- Clinical course and outcomes of Iranian children with juvenile dermatomyositis and polymyositis.Clinical rheumatology · 2014Article
- Diagnosis, pathogenesis and treatment of myositis: recent advances.Clinical and experimental immunology · 2014Review
- Connective tissue ulcers.Journal of tissue viability · 2013Article
- Juvenile Dermatomyositis in an 11 Year Old Nigerian-Boy: A Case Report and Review of Literature.Nigerian medical journal : journal of the Nigeria Medical AssociationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Juvenile dermatomyositis (JDM) is a rare but complex and potentially life-threatening autoimmune disease of childhood, primarily affecting proximal muscles and skin. Although the cause of JDM remains unknown it is clear that genetic and environmental influences play a role in the aetiology. In contrast to adults with dermatomyositis, children with JDM are more likely to have complications that are thought to indicate a vasculopathic process, such as severe skin disease, with ulceration or calcinosis, gut vasculopathy or central nervous system disease. New treatments are much needed and are becoming available and being tested through international multicentre trials. This review will focus on recent insights into pathogenesis, the assessment of the disease in children and the modern approach to its treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.